Email this article 
Hide
Show all
Case Report
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
Submitted: 19 December 2019 | Published: 02 July 2020
About the author(s)
Kairoonisha Mahomed, Private practice, Johannesburg, South AfricaCarole L. Wallis, Department of Molecular Pathology, BARC-SA and Lancet Laboratories, Johannesburg, South Africa
Liezl Dunn, Aid for AIDS Management (Pty) Ltd, Cape Town, South Africa
Shavani Maharaj, Aid for AIDS Management (Pty) Ltd, Cape Town, South Africa
Gary Maartens, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Graeme Meintjes, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Abstract
Introduction: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment-experienced patients unless there was prior use of a first-generation integrase inhibitor.
Patient presentation: A 38-year-old woman diagnosed with tuberculosis was switched to a second-line antiretroviral regimen of zidovudine, lamivudine and dolutegravir 50 mg 12-hourly together with rifampicin-based TB treatment. Based on treatment history and a previous resistance test there was resistance to lamivudine but full susceptibility to zidovudine. The patient did not suppress her viral load on this regimen and later admitted to only taking dolutegravir 50 mg in the morning because of insomnia.
Management and outcome: A second resistance test was performed which showed intermediate level of resistance to dolutegravir. Her regimen was changed to tenofovir, emtricitabine and ritonavir-boosted atazanavir with rifabutin replacing rifampicin for the remainder of her TB treatment. She achieved viral suppression on this regimen.
Conclusion: To our knowledge this is the first case report from South Africa of emergent dolutegravir resistance in a treatment-experienced, integrase inhibitor-naïve patient. Factors that may have contributed to resistance emergence in this patient were that there was only one fully active nucleoside reverse transcriptase inhibitor in the regimen and lower exposure to dolutegravir because of the reduced dosing frequency while on rifampicin.
Keywords
Metrics
Total abstract views: 5198Total article views: 5255
Crossref Citations
1. Real‐world use and outcomes of dolutegravir‐containing antiretroviral therapy in HIV and tuberculosis co‐infection: a site survey and cohort study in sub‐Saharan Africa
Matthew L. Romo, Ellen Brazier, Dominique Mahambou‐Nsondé, Reneé De Waal, Christine Sekaggya‐Wiltshire, Cleophas Chimbetete, Winnie R. Muyindike, Gad Murenzi, Cordelia Kunzekwenyika, Thierry Tiendrebeogo, Josephine A. Muhairwe, Patricia Lelo, Anastase Dzudie, Christelle Twizere, Idiovino Rafael, Oliver C. Ezechi, Lameck Diero, Marcel Yotebieng, Lukas Fenner, Kara K. Wools‐Kaloustian, N. Sarita Shah, Denis Nash
Journal of the International AIDS Society vol: 25 issue: 7 year: 2022
doi: 10.1002/jia2.25961
2. Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program
Hope Kanise, Joep J. van Oosterhout, Pachawo Bisani, John Songo, Bilaal W. Matola, Chifundo Chipungu, Katherine Simon, Carrie Cox, Mina C. Hosseinipour, Jean-Batiste Sagno, Risa M. Hoffman, Claudia Wallrauch, Sam Phiri, Kim Steegen, Andreas Jahn, Rose Nyirenda, Tom Heller
Viruses vol: 16 issue: 1 first page: 29 year: 2023
doi: 10.3390/v16010029
3. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir
Ingrid A. Beck, Ceejay L. Boyce, Marley D. Bishop, Yen L. Vu, Amanda Fung, Sheila Styrchak, Nuttada Panpradist, Barry R. Lutz, Lisa M. Frenkel
Viruses vol: 16 issue: 7 first page: 1162 year: 2024
doi: 10.3390/v16071162
4. HIV Dolutegravir resistance and multiclass failure in Mozambique: findings from a real-world cohort
Fausto Ciccacci, Anna Maria Doro Altan, Noorjehan Majid, Stefano Orlando, Elton Uamusse, Marcia Rafael, Zita Sidumo, Paola Germano, Giovanni Guidotti, Carlo Federico Perno
BMC Infectious Diseases vol: 25 issue: 1 year: 2025
doi: 10.1186/s12879-025-11639-2
5. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania
Shimba Henerico, Eric Lyimo, Abel N Makubi, Daniel Magesa, Bernard Desderius, Andreas Mueller, John Changalucha, Samuel E Kalluvya, Gert Van Zyl, Wolfgang Preiser, Stephen E Mshana, Christa Kasang
Journal of Antimicrobial Chemotherapy vol: 77 issue: 11 first page: 3138 year: 2022
doi: 10.1093/jac/dkac295
6. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis
Ezechiel Ngoufack Jagni Semengue, Maria Mercedes Santoro, Valantine Ngum Ndze, Aude Christelle Ka’e, Bouba Yagai, Alex Durand Nka, Beatrice Dambaya, Desiré Takou, Georges Teto, Lavinia Fabeni, Vittorio Colizzi, Carlo-Federico Perno, Francesca Ceccherini-Silberstein, Joseph Fokam, Kévin Jean
PLOS Global Public Health vol: 2 issue: 10 first page: e0000826 year: 2022
doi: 10.1371/journal.pgph.0000826
7. Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART
Richard A Murphy, Pradeep H Bedesi, Nirmala Perumal, Bernadett I Gosnell, Timothy J Hatlen, Jaysingh Brijkumar
Open Forum Infectious Diseases vol: 11 issue: 7 year: 2024
doi: 10.1093/ofid/ofae321
8. Research Progress on Influencing Factors of AIDS Curative Effect
金玲 刘
Advances in Clinical Medicine vol: 13 issue: 07 first page: 11153 year: 2023
doi: 10.12677/ACM.2023.1371557
9. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
Kaiming Tao, Soo-Yon Rhee, Carolyn Chu, Ava Avalos, Amrit K. Ahluwalia, Ravindra K. Gupta, Michael R. Jordan, Robert W. Shafer
Viruses vol: 15 issue: 9 first page: 1932 year: 2023
doi: 10.3390/v15091932
10. Dolutegravir resistance in sub-Saharan Africa: should resource-limited settings be concerned for future treatment?
Doreen Kamori, Godfrey Barabona
Frontiers in Virology vol: 3 year: 2023
doi: 10.3389/fviro.2023.1253661
11. Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe
Tendai Washaya, Benjamin Chimukangara, Justin Mayini, Sandra Bote, Nyasha Chin’ombe, Shungu Munyati, Justen Manasa
Viruses vol: 17 issue: 10 first page: 1348 year: 2025
doi: 10.3390/v17101348